• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

海藻酸钠-壳聚糖微球的析因设计分析与优化。

Factorial design analysis and optimisation of alginate-Ca-chitosan microspheres.

机构信息

Faculty of Pharmacy, Institute of Pharmaceutical Technology, University Ss Cyril and Methodius, Vodnjanska 17, 1000 Skopje, Macedonia.

出版信息

J Microencapsul. 2013;30(1):81-92. doi: 10.3109/02652048.2012.700957. Epub 2012 Jul 3.

DOI:10.3109/02652048.2012.700957
PMID:22746546
Abstract

The purpose of this study was to apply factorial design in order to determine the influence of the formulation factors and their interactions on several responses such as particle size, dissolution behaviour at pH 1.2 and pH 7.4 as well as production yield, during the development of budesonide loaded, chitosan coated Ca-alginate microparticles (MPs) intended for treatment of inflammatory diseases in the gastrointestinal tract. Produced drug-loaded MPs were spherical in shape, had smooth surfaces with low porosity and size range between 5 and 11 µm. Production yield for the formulations from the design varied from 19% to 50%. Optimisation was performed using central composite design setting the targets: particle size at 5.5 µm, maximised yield, suppressed dissolution at pH 1.2 and sustained release at pH 7.4. The optimised batches were identified with a combined desirability value of 0.967.

摘要

本研究旨在应用析因设计,以确定配方因素及其相互作用对多个响应的影响,如粒径、在 pH 1.2 和 pH 7.4 时的溶解行为以及生产收率,在开发用于治疗胃肠道炎症性疾病的负载布地奈德的壳聚糖包被海藻酸钙微球(MPs)过程中。所制备的载药 MPs 呈球形,表面光滑,孔隙率低,粒径在 5 至 11 μm 之间。设计的制剂的生产收率在 19%至 50%之间变化。通过使用中心复合设计进行优化,设定目标为:粒径为 5.5 μm,收率最大化,在 pH 1.2 时抑制溶解,在 pH 7.4 时持续释放。优化批次的综合适宜性值为 0.967。

相似文献

1
Factorial design analysis and optimisation of alginate-Ca-chitosan microspheres.海藻酸钠-壳聚糖微球的析因设计分析与优化。
J Microencapsul. 2013;30(1):81-92. doi: 10.3109/02652048.2012.700957. Epub 2012 Jul 3.
2
An investigation of formulation factors affecting feasibility of alginate-chitosan microparticles for oral delivery of naproxen.研究影响海藻酸钠-壳聚糖微球口服递药可行性的配方因素。
Arch Pharm Res. 2011 Jun;34(6):919-29. doi: 10.1007/s12272-011-0609-y. Epub 2011 Jul 2.
3
Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex.基于设计的质量控制方法用于开发壳聚糖-海藻酸钙微球用于塞来昔布-羟丙基-β-环糊精-PVP 复合物的结肠递药。
Eur J Pharm Biopharm. 2012 Jan;80(1):67-75. doi: 10.1016/j.ejpb.2011.08.002. Epub 2011 Aug 16.
4
Chitosan oligosaccharide as prospective cross-linking agent for naproxen-loaded Ca-alginate microparticles with improved pH sensitivity.壳寡糖作为一种有前景的交联剂用于载萘普生的 Ca-海藻酸微球,以提高其对 pH 的敏感性。
Drug Dev Ind Pharm. 2013 Jan;39(1):77-88. doi: 10.3109/03639045.2012.658813. Epub 2012 Feb 18.
5
Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin.海藻酸钠-壳聚糖微球的制备及其用于胰岛素口服给药的评价。
Eur J Pharm Biopharm. 2011 Jan;77(1):11-9. doi: 10.1016/j.ejpb.2010.09.016. Epub 2010 Oct 7.
6
Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone.含泼尼松龙的藻酸盐/壳聚糖微粒的制备及其黏膜黏附性能的体外评价
Int J Pharm. 2006 Apr 7;312(1-2):113-8. doi: 10.1016/j.ijpharm.2006.01.003. Epub 2006 Feb 21.
7
Protein micro and nanoencapsulation within glycol-chitosan/Ca²+/alginate matrix by spray drying.喷雾干燥法制备壳聚糖/海藻酸钠基质中的蛋白质微胶囊和纳米胶囊。
Drug Dev Ind Pharm. 2011 Jun;37(6):619-27. doi: 10.3109/03639045.2010.533681. Epub 2011 Mar 30.
8
Preparation of chitosan/alginate/calcium complex microparticles loaded with lactoferrin and their efficacy on carrageenan-induced edema in rats.载乳铁蛋白的壳聚糖/海藻酸钠/钙复合物微球的制备及其对卡拉胶诱导的大鼠水肿的疗效。
Drug Dev Ind Pharm. 2010 Aug;36(8):879-84. doi: 10.3109/03639040903567109.
9
Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa.负载布地奈德的壳聚糖包被的海藻酸钙微粒,用于递送至炎症性结肠黏膜。
Eur J Pharm Biopharm. 2008 Mar;68(3):565-78. doi: 10.1016/j.ejpb.2007.06.007. Epub 2007 Jun 14.
10
Alginate microspheres of isoniazid for oral sustained drug delivery.用于口服持续给药的异烟肼海藻酸盐微球。
Int J Pharm. 2007 Apr 4;334(1-2):71-7. doi: 10.1016/j.ijpharm.2006.10.024. Epub 2006 Oct 21.

引用本文的文献

1
Preparation and property evaluation of oral colon targeted protein delivery system with sodium alginate and chitosan.海藻酸钠和壳聚糖口服结肠靶向蛋白质递送系统的制备与性能评价
Sci Rep. 2025 Jul 1;15(1):21598. doi: 10.1038/s41598-025-04983-5.
2
Effect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation.实验参数对用于卡介苗包封的海藻酸盐/壳聚糖微粒的影响。
Mar Drugs. 2016 May 11;14(5):90. doi: 10.3390/md14050090.
3
The effect of nanoemulsion as a carrier of hydrophilic compound for transdermal delivery.
纳米乳剂作为亲水性化合物经皮给药载体的作用。
PLoS One. 2014 Jul 28;9(7):e102850. doi: 10.1371/journal.pone.0102850. eCollection 2014.
4
Effect of microemulsions on transdermal delivery of citalopram: optimization studies using mixture design and response surface methodology.微乳液对西酞普兰经皮传递的影响:使用混合设计和响应面法的优化研究。
Int J Nanomedicine. 2013;8:2295-304. doi: 10.2147/IJN.S43474. Epub 2013 Jun 25.
5
Development of novel cationic chitosan-and anionic alginate-coated poly(D,L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol.新型阳离子壳聚糖和阴离子海藻酸钠共包被聚(D,L-乳酸-共-乙醇酸)纳米粒的制备及其对白藜芦醇的控制释放和光保护作用。
Int J Nanomedicine. 2012;7:5501-16. doi: 10.2147/IJN.S36684. Epub 2012 Oct 17.